Royal Bank Of Canada Sellas Life Sciences Group, Inc. Transaction History
Royal Bank Of Canada
- $422 Billion
- Q1 2024
A detailed history of Royal Bank Of Canada transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 223 shares of SLS stock, worth $265. This represents 0.0% of its overall portfolio holdings.
Number of Shares
223
Previous 358
37.71%
Holding current value
$265
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SLS
# of Institutions
35Shares Held
8.03MCall Options Held
2.52MPut Options Held
24.7K-
Anson Funds Management LP Dallas, TX4.83MShares$5.75 Million0.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$1.8 Million0.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$367,0743.71% of portfolio
-
Black Rock Inc. New York, NY278KShares$331,0790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA273KShares$324,9440.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.5M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...